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Summary
Objective: Mutations in the aggrecan gene (ACAN) have been identified in two auto-
somal dominant skeletal dysplasias, spondyloepiphyseal dysplasia, Kimberley type 
(SEDK), and osteochondritis dissecans, as well as in a severe recessive dysplasia, 
spondyloepimetaphyseal dysplasia, aggrecan type. Next- generation sequencing 
(NGS) has aided the identification of heterozygous ACAN mutations in individuals 
with short stature, minor skeletal defects and mild facial dysmorphisms, some of 
whom have advanced bone age (BA), poor pubertal spurt and early growth cessation 
as well as precocious osteoarthritis.
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1  | INTRODUC TION
Longitudinal bone growth occurs at the growth plate as a result of 
chondrogenesis. It is regulated by a complex network of signals from 
endocrine and paracrine systems as well as interactions between 
cellular growth factors and extracellular matrix. Mutations in many 
of these pathways result in growth delay and/or skeletal defects.
Short stature is one of the most common reasons for referral 
to a paediatric endocrinologist. Next- generation sequencing (NGS) 
has permitted the identification of genetic defects in subgroups of 
short stature individuals, including heterozygous mutations in the 
aggrecan gene (ACAN).
Aggrecan is a major structural component of the cartilage 
growth plate. Until recently, ACAN mutations had been observed in 
a few families with spondyloepiphyseal dysplasia, Kimberley type 
(SEDK, MIM 608361)1; spondyloepimetaphyseal dysplasia, aggre-
can type (SEMD, MIM 612813)2; and osteochondritis dissecans 
(MIM 165800).3 More recently, through the implementation of NGS, 
heterozygous ACAN mutations have been reported in individuals 
with a milder skeletal dysplasia, presenting with short stature and 
Design and methods: This study involves clinical and genetic characterization of 16 
probands with heterozygous ACAN variants, 14 with short stature and mild skeletal 
defects (group 1) and two with SEDK (group 2). Subsequently, we reviewed the litera-
ture to determine the frequency of the different clinical characteristics in ACAN- 
positive individuals.
Results: A total of 16 ACAN variants were located throughout the gene, six patho-
genic mutations and 10 variants of unknown significance (VUS). Interestingly, brachy-
dactyly was observed in all probands. Probands from group 1 with a pathogenic 
mutation tended to be shorter, and 60% had an advanced BA compared to 0% in 
those with a VUS. A higher incidence of coxa valga was observed in individuals with a 
VUS (37% vs 0%). Nevertheless, other features were present at similar frequencies.
Conclusions: ACAN should be considered as a candidate gene in patients with short 
stature and minor skeletal defects, particularly those with brachydactyly, and in pa-
tients with spondyloepiphyseal dysplasia. It is also important to note that advanced 
BA and osteoarticular complications are not obligatory conditions for aggrecanopa-
thies/aggrecan- associated dysplasias.
K E Y W O R D S
ACAN, aggrecan, brachydactyly, short stature, skeletal dysplasia
F IGURE  1 Structure of ACAN and the locations of the variants identified in the 16 probands. The G1 region encoded by exons 3- 6, the 
IGD region by exon 7, the G2 region by exons 8- 10, the GAG (KS- CS1- CS2) attachment region encoded by exons 11- 12, while the G3 region 
encoded by exons 13- 19. Missense variants written in black, while premature truncating (nonsense, frameshift, splicing) mutations written 
in red. Mutations corresponding to SEDK written in blue. Families with osteoarthritis and/or discopathy underlined [Colour figure can be 
viewed at wileyonlinelibrary.com]
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advanced bone age (BA).4-10 This led to the creation of an International 
Aggrecan Consortium for the clinical and genetic evaluation of 103 
ACAN heterozygotes from 20 families.6 Height appeared to be less 
affected during childhood (median −2 SDS), and most had advanced 
BA compared to chronological age (CA).
Aggrecan consists of an N- terminal domain, two globular do-
mains (G1 and G2), two interglobular domains (CS and KS attach-
ment regions), a selectin- like domain (G3) and a C- terminal domain.11 
Mutations are located throughout the protein, and no genotype- 
phenotype correlations have been observed.6,10 The pathogenic 
mechanisms for the accelerated bone maturation, cartilage degrada-
tion and the clinical heterogeneity remain elusive.
We present a retrospective study of the clinical and genetic find-
ings of 16 probands with heterozygous ACAN variants, detected during 
routine genetic studies using a skeletal dysplasia NGS panel. We also 
review all cases reported in the literature to determine the frequency 
of the different clinical characteristics related to aggrecanopathies.
2  | PATIENTS AND METHODS
All participants provided informed consent for the conducted stud-
ies, and the ethical approval was obtained from the Hospital La Paz 
Ethical Committee.
The 16 probands were referred for molecular study from Spanish 
and Portuguese endocrinology and genetic clinics. Ten formed part 
of a cohort of 100 children with short stature and mild skeletal de-
fects in either the proband or one of their parents, in whom SHOX 
defects had been previously excluded using MLPA (P018G1, MRC 
Holland) and DNA sequencing. Endocrine disorders including GH- 
IGF1- related conditions were also excluded by biochemical analysis. 
The remaining six probands were referred for routine skeletal dys-
plasia genetic diagnosis (n > 1000 patients). SHOX mutations were 
similarly excluded in four of these, not conducted in probands 15- 
16. BA and skeletal surveys were carried out. Blood samples were 
extracted from the proband and family members, when available.
All probands were analysed using a custom- designed skeletal dys-
plasia next- generation sequencing (NGS) panel, SKELETALSEQ.V3- 6 
(n = 315- 368 genes) and sequenced on a MiSeq/NextSeq sequencer 
(Illumina, San Diego, CA, USA). Bioinformatic analyses were conducted 
as previously described.11 Conservation, pathogenicity prediction 
analysis and population frequences of the identified ACAN variants 
were carried out using CADD V1.3 (http://cadd.gs.washington.edu/), 
GerpRS (http://mendel.stanford.edu/SidowLab/downloads/gerp/) and 
Alamut V2.10 (Interactive Biosoftware, France) and gnomAD data-
base (http://gnomad.broadinstitute.org). Variants were subsequently 
validated by Sanger sequencing as was family testing. Kinship was 
confirmed using microsatellite marker analysis (Devyser Complete QF- 
PCR, Stockholm, Sweden).
After the identification of an ACAN variant, each referring clini-
cian was asked to complete a specific aggrecanopathy clinical ques-
tionnaire including personal and familial records, anthropometric 
measures, facial dysmorphisms, age of puberty onset and pubertal P
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spurt and other associated medical conditions, similar to that pre-
viously published.6 Advanced BA was defined as a BA greater than 
1 year compared to the CA, while delayed BA was defined as BA 
less than 1 year relative to the CA. Brachydactyly was defined as 
short metacarpals and/or fingers. The clinical data, BA and skele-
tal surveys were then revised by three experts (LS- M, AO and MP). 
Subsequently, the 16 probands were divided into two clinical groups: 
those presenting with short stature and mild skeletal defects (group 
1, probands 1- 14) and two with SEDK (group 2, probands 15- 16).
3  | RESULTS
3.1 | Molecular genetics
A total of 16 heterozygous ACAN variants were identified (Figure 1, 
Table 1). No other pathogenic mutation or variant of unknown 
significance (VUS) associated with short stature and skeletal de-
fects, including brachydactyly, was detected in the probands. Six 
variants were classified as pathogenic mutations (4 nonsense, 
TABLE  2 Clinical characteristics of probands from group 1 with short stature and mild skeletal defects. The total number presenting  
each clinical feature is based on paediatric cases (n = 13), thus excluding adult patient 14
Anthropometric data Facial dysmorphisms Skeletal findings
Proband
Geographical 
origin
Mutation cDNA 
(protein)
Age  
(years)
Gender 
(F/M)
SGA 
(Y/N)
Height 
(SDS)
Target 
height 
(SDS) SH/H BA vs CA Macrocephaly
Frontal 
bossing
Mid- facial  
hypoplasia
Depressed  
nasal bridge
Broad 
nose and 
philtrum
Thin 
lips
High 
arched 
palate Hypertelorism Epicantus
Triangular 
face
Puberty 
spurt 
(Menarche) Brachydactyly Hyperlordosis
Coxa 
valga
Other skeletal 
findings
Precocious 
arthropathy or 
discopathy in 
family member
Affected 
family 
members (n)
Affected 
family 
members 
height 
(SDS)
1 Sp c.61G>T  
(p.Glu21*)
4.5 F N −3.5 −3.0 0.56 +1.5 + + + − − − − − − − − + + − − − 2 −3.0 
−1.5
2 Sp c.371G>A 
(p.Arg124His)
8.0 F N −3.7 −2.4 0.54 −2 − − − − + + + − − − − + + + − − 1 −2.7
3 Ec c.742G>A 
(p.Ala248Thr)
14.5 M N −1.8 −2.6 0.52 0 − − − − − − − − − − NA + − + Mildly flattened 
capital femoral 
epiphyses, 
slender femora
Osteoarthritis 
and discopathy 
in mother
1 −3.0
4 Sp c.903G>C 
(p.Trp301Cys)
7.0 F N −3.5 −3.6 NA 0 − + + + − − − − − − − + − + Slender femora 
Osteochondral 
knee mild 
defects
Familiar 
osteochondri-
tis dissecans in 
affected father 
and uncle
2 −4.4 
−3.8
5 Sp c.1608C>A 
(p.Tyr536*)
4.5 F N −3.5 −3.0 0.60 0 − − − − − − − − − − − + − − Osteochondral 
knee mild 
defects
Osteoarthritis in 
father
1 −4.5
6 Ch c.1930G>A 
(p.Gly644Ser)
16.0 F N −2.1 −2.0 0.57 0 − − − − − − − − − − NA + − − Madelung 
deformity, 
short femoral 
necks, mild 
epiphyseal 
knee defects
− 1 −3.7
7 Sp c.1948G>A 
(p.Val650Met)
12.0 M N −2.6 −1.4 0.52 −3 − − − + − + − − + − − + − − − − 1 −2.6
8 Sp c.2218A>T 
(p.Thr740Ser)
3.0 M N −3.2 NA 0.57 0 − + + − − − + − − + − + − − − − 1 −3.7
9 Sp c.2369C>G 
(p.Ser790*)
14.5 M Y −2.2 −0.6 0.52 +2 − + − − + − − + − − NA + + − − − − −
10 Sp c.6142C>G 
(p.Pro2048Ala)
12.5 F Y −2.2 −2.1 NA 0 − − − − − − − − − − NA + − − − − 1 −2.3
11 Sp c.7269delG 
(p.Glu2424 fs*5)
1.5 M N −3.0 −3.2 NA +2 − − − + − − − − − − − + − − − − 2 −5.8 
−3.8
12 Sp c.7276G>A 
(p.Glu2426Lys)
8.5 F Y −2.5 −1.8 NA 0 − + − + − − − − − − − + − − Cone- shaped 
epiphysis
− 1 −1.79
13 Sp c.7276G>T 
(p.Gly2426*)
18.0 M Y −4.3 −3.4 0.54 0 + − − − − − − − − − Poor + − − Short femoral 
neck
− 2 −5.0 
−3.7
14 Sp c.7342G>A 
(p.Gly2448Arg)
46 F NA −3.7 −4.3 0.52 NA − + + − − − − − − − Poor (11y) + − − − − 2 −4.3 
−3.5
TOTAL (paediatric 
cohort, n=13)
Median 
10.2
7F
6M
4 −2.9 −2.5 0.54 3 Adv
10 Eq/Del
2 5 3 4 2 2 2 1 1 1 − 13 3 3 6 3 families 18 Median 
−3.77
Geographical origin: Sp, Spain; Ec, Ecuador; Ch, China. Gender: M, male; F, female. SGA: N, no; Y, yes. SH/H, sitting height/height.
BA vs CA.
+, BA > 1 year CA (advanced).
0, BA = CA (equal; between +1 and −1 year).
−, BA < 1 year CABA (delayed).
NA, Not available.
Facial dysmorphisms and skeletal findings: +, present; −, absent.
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1 frameshift and 1 splicing), while the remaining ten were clas-
sified as VUS (Table 1) using the American Society of College of 
Genetics and Genomics (ACMG) recommendations for classifying 
variants.12
Family testing was carried out in all 16 probands. Mutations were 
inherited in all but one case (proband 9), which appears to have arisen 
as a de novo event or due to germinal mosaicism. The variants were 
identified in a total of 20 family members, 19 adults and one child, 
all with short stature and/or mild skeletal defects or SEDK (fathers 
of probands 15 and 16). Unfortunately, further cosegregation studies 
from multiple generations were not possible.
3.2 | Clinical group 1 (patients 1- 14) with short 
stature and mild skeletal defects
Thirteen of the 14 probands were children (age range 1.5- 18 years, 
median 10.2 years). Probands 1 and 13 were previously included 
in the International Aggregation Consortium study.6 Clinical 
TABLE  2 Clinical characteristics of probands from group 1 with short stature and mild skeletal defects. The total number presenting  
each clinical feature is based on paediatric cases (n = 13), thus excluding adult patient 14
Anthropometric data Facial dysmorphisms Skeletal findings
Proband
Geographical 
origin
Mutation cDNA 
(protein)
Age  
(years)
Gender 
(F/M)
SGA 
(Y/N)
Height 
(SDS)
Target 
height 
(SDS) SH/H BA vs CA Macrocephaly
Frontal 
bossing
Mid- facial  
hypoplasia
Depressed  
nasal bridge
Broad 
nose and 
philtrum
Thin 
lips
High 
arched 
palate Hypertelorism Epicantus
Triangular 
face
Puberty 
spurt 
(Menarche) Brachydactyly Hyperlordosis
Coxa 
valga
Other skeletal 
findings
Precocious 
arthropathy or 
discopathy in 
family member
Affected 
family 
members (n)
Affected 
family 
members 
height 
(SDS)
1 Sp c.61G>T  
(p.Glu21*)
4.5 F N −3.5 −3.0 0.56 +1.5 + + + − − − − − − − − + + − − − 2 −3.0 
−1.5
2 Sp c.371G>A 
(p.Arg124His)
8.0 F N −3.7 −2.4 0.54 −2 − − − − + + + − − − − + + + − − 1 −2.7
3 Ec c.742G>A 
(p.Ala248Thr)
14.5 M N −1.8 −2.6 0.52 0 − − − − − − − − − − NA + − + Mildly flattened 
capital femoral 
epiphyses, 
slender femora
Osteoarthritis 
and discopathy 
in mother
1 −3.0
4 Sp c.903G>C 
(p.Trp301Cys)
7.0 F N −3.5 −3.6 NA 0 − + + + − − − − − − − + − + Slender femora 
Osteochondral 
knee mild 
defects
Familiar 
osteochondri-
tis dissecans in 
affected father 
and uncle
2 −4.4 
−3.8
5 Sp c.1608C>A 
(p.Tyr536*)
4.5 F N −3.5 −3.0 0.60 0 − − − − − − − − − − − + − − Osteochondral 
knee mild 
defects
Osteoarthritis in 
father
1 −4.5
6 Ch c.1930G>A 
(p.Gly644Ser)
16.0 F N −2.1 −2.0 0.57 0 − − − − − − − − − − NA + − − Madelung 
deformity, 
short femoral 
necks, mild 
epiphyseal 
knee defects
− 1 −3.7
7 Sp c.1948G>A 
(p.Val650Met)
12.0 M N −2.6 −1.4 0.52 −3 − − − + − + − − + − − + − − − − 1 −2.6
8 Sp c.2218A>T 
(p.Thr740Ser)
3.0 M N −3.2 NA 0.57 0 − + + − − − + − − + − + − − − − 1 −3.7
9 Sp c.2369C>G 
(p.Ser790*)
14.5 M Y −2.2 −0.6 0.52 +2 − + − − + − − + − − NA + + − − − − −
10 Sp c.6142C>G 
(p.Pro2048Ala)
12.5 F Y −2.2 −2.1 NA 0 − − − − − − − − − − NA + − − − − 1 −2.3
11 Sp c.7269delG 
(p.Glu2424 fs*5)
1.5 M N −3.0 −3.2 NA +2 − − − + − − − − − − − + − − − − 2 −5.8 
−3.8
12 Sp c.7276G>A 
(p.Glu2426Lys)
8.5 F Y −2.5 −1.8 NA 0 − + − + − − − − − − − + − − Cone- shaped 
epiphysis
− 1 −1.79
13 Sp c.7276G>T 
(p.Gly2426*)
18.0 M Y −4.3 −3.4 0.54 0 + − − − − − − − − − Poor + − − Short femoral 
neck
− 2 −5.0 
−3.7
14 Sp c.7342G>A 
(p.Gly2448Arg)
46 F NA −3.7 −4.3 0.52 NA − + + − − − − − − − Poor (11y) + − − − − 2 −4.3 
−3.5
TOTAL (paediatric 
cohort, n=13)
Median 
10.2
7F
6M
4 −2.9 −2.5 0.54 3 Adv
10 Eq/Del
2 5 3 4 2 2 2 1 1 1 − 13 3 3 6 3 families 18 Median 
−3.77
Geographical origin: Sp, Spain; Ec, Ecuador; Ch, China. Gender: M, male; F, female. SGA: N, no; Y, yes. SH/H, sitting height/height.
BA vs CA.
+, BA > 1 year CA (advanced).
0, BA = CA (equal; between +1 and −1 year).
−, BA < 1 year CABA (delayed).
NA, Not available.
Facial dysmorphisms and skeletal findings: +, present; −, absent.
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characteristics are shown in Table 2. Anthropometric measurements 
were assessed in the 13 children of group 1. The median height SDS 
was below average (−2.9), sitting height- to- height ratio was in the 
normal range (0.54), and BMI was −0.31 SDS. Advanced BA was ob-
served in three probands, while equal or delayed BA with respect to 
CA was determined in ten. Three probands had reached their final 
height, two of whom had had a poor pubertal spurt. Examples of 
growth patterns are shown in Figure S1. Radiological features and 
hand photographs are shown in Figures S2 and S3, respectively. 
Brachydactyly (short fingers and/or short metacarpals) was ob-
served in all probands in group 1. Seven probands (53%) showed a 
similar phenotype with frontal bossing, depressed nasal bridge and/
or mid- facial dysplasia (Table 2). Three of the patients (probands 2, 
9 and 12) have recently initiated growth hormone therapy, but no 
response data are currently available. To determine whether the 
clinical characteristics were similar or different in individuals with 
a clearly pathogenic mutation compared to those with a VUS, we 
made a comparison of the clinical and radiological characteristics of 
these probands from group 1 (Table 3).
3.3 | Group 2 (probands 15- 16)—SEDK
Heterozygous ACAN mutations were identified in the two probands 
with moderate skeletal anomalies including platyspondyly, who 
were subsequently diagnosed as having SEDK (Table 1). Proband 
15 was found to have a mutation in the canonical splice acceptor 
site of intron 1 (c.- 7- 2A>C), which is predicted to result in the re-
moval of exon 2, where the initiation codon is located. We demon-
strated, using a minigene assay, that this mutation indeed ablated 
the intron 1 splice acceptor site, thus confirming the pathogenicity 
of this variant (Figure S4). The second case, proband 16, has a mis-
sense variant (VUS) in ACAN (p.Thr533Ile). Clinical and radiological 
characteristics of both probands are shown in Table 4 and Figure 
S2, respectively.
4  | DISCUSSION
A total of 16 heterozygous variants were detected throughout 
ACAN, 14 in individuals with short stature, mild skeletal defects and/
or facial dysmorphisms (group 1) and two with SEDK (group 2). No 
other mutation/variant was identified in the skeletal dysplasia pa-
tient in the 16 probands, which could explain their phenotype. As 
functional characterization is not currently feasible for confirming 
the pathogenicity of the ACAN VUS, we compared the clinical fea-
tures in probands from group 1 with a pathogenic mutation (non-
sense, frameshift, splicing, n = 5) and those with VUS (missense 
variants, n = 8) (Table 3). Individuals with a pathogenic mutation 
were shorter (median −3.33 vs −2.7 SDS), and 60% had an advanced 
BA compared to 0% in those with a VUS. Advanced BA:CA was only 
observed in 3/5 individuals with a pathogenic mutation; thus, two 
individuals had a BA equal or delayed with respect to the CA. To 
date, a total of 58 probands and 106 family members (total = 164 
heterozygous ACAN-positive individuals with short stature and mild 
skeletal defects) have been reported in this study and in the litera-
ture (Table 5).4-10. Although advanced BA is a good indicator for the 
presence of mutations in ACAN, it cannot be the principal selection 
criteria. The other major difference was that a third of the individuals 
with a VUS had coxa valga, whereas no individual with a pathogenic 
mutation presented with this clinical feature. Nevertheless, other 
features such as skeletal defects, facial dysmorphisms and preco-
cious arthropathy or discopathy were present at similar frequen-
cies in both variant classification groups. An interesting observation 
and in contrast to previous data, brachydactyly was observed in all 
probands.
After analysing the individuals according to the variant classifi-
cation, we conducted a study of the clinical features of the probands 
and affected family members from group 1 (n = 32; 14 children and 
18 adults). No sex or ethnic differences were observed. Only 23% of 
the children had advanced BA, once again significantly lower than 
that previously described (Table 5). The degree of short stature was 
also very variable. Another previously undescribed feature was the 
presence of mild hip abnormalities in five probands (38%). Parents of 
two of these probands suffer with osteoarthritis. Osteoarthritis and 
disc disease were uncommon in our cohort with only three parents 
having these medical complications (23%) (Table 5).
Clinical heterogeneity occurred in some families, as previously 
reported in a few cases.6,10 Proband 3 (p.Ala248Thr- VUS) presents 
with normal stature although in the lower range (−1.8 SDS), BA is 
equal to CA but has brachydactyly and minor skeletal defects. He 
has not yet reached adult height, and early growth cessation occurs 
in this growth disorder. His mother, with the same variant, pres-
ents with short stature (−3 SDS), precocious osteoarthritis and dis-
copathy. Thus, the differences in height and clinical presentation 
are likely to be associated with age. In a similar way, proband 12 
(p.Glu2426Lys- VUS) presents with short stature (−2.5 SDS), 
BA equal to CA, mild dysmorphic features and skeletal defects. 
Her father has the same variant but has normal stature although 
within the lower limit (−1.79 SDS) and only brachydactyly. This 
clinical heterogeneity is similarly observed in other skeletal dys-
plasias such as those associated with heterozygous SHOX or NPR2 
mutations.13
Two heterozygous ACAN variants (1 pathogenic and 1 VUS) 
were identified in two individuals with SEDK. To date, only one 
SEDK case with an ACAN mutation in the CS1 domain has been 
reported in the literature.1 Prior to the implementation of NGS, 
patients with this form of spondyloepiphyseal dysplasia were gen-
erally tested for mutations in COL2A1 and, if negative, remained 
molecularly undiagnosed. Thus, further cases may be identified in 
the future.
Interestingly, proband 6 presented with Madelung deformity and 
proband 15 and his father, considered to have SEDK, have curved 
radii and limited elbow extension. Madelung deformity is typically 
observed in individuals with Léri- Weill dyschondrosteosis (MIM 
127300), isolated or due to post- traumatic conditions.14 SHOX de-
fects have been excluded in all probands. This observation is not 
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that surprising as SHOX binds to SOX5 and SOX6 which along with 
SOX9 (SOX trio) activate an aggrecan enhancer, thus participating in 
common regulatory pathways in chondrogenesis.15
The description of our cohort supports the undertaking of a de-
tailed clinical examination and skeletal survey in short stature indi-
viduals with suspicion of a mild skeletal dysplasia. Our observation 
of an association with brachydactyly may help clinicians to request 
genetic analysis of ACAN.
For now, the diagnosis of this dysplasia is paramount for patients 
and their families. Individuals with ACAN mutations are at risk of short 
stature, early growth cessation and poor pubertal spurt, and other 
health- related problems such as obesity and orthopaedic problems 
should be prevented or their effects reduced. Careful monitoring 
of patients with ACAN mutations may help us to identify important 
genotype- phenotype correlations and to understand their long- 
term clinical outcomes. Additional familial studies, analysis of larger 
cohorts, generation of animal models and functional analysis will be 
also required to determine the incidence of ACAN mutations and the 
pathogenic mechanism(s).16
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